Pharmaceuticals
GHIT-backed Innovation Achieves Landmark: New Treatment Option for Schistosomiasis Reaches Preschool-Aged Children
TOKYO, March 5, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund is today announcing a significant milestone: the first administration of arpraziquantel to preschool-aged children inUganda, in an implementation science setting. This new pediatric treatment for schistosomi...
2025-03-05 09:00
2134
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin")
REROVOT, Israel, March 4, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation inChina for the treatment of fat reduction in the submental area. Submental fat...
2025-03-04 09:00
1829
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology. In ...
2025-03-04 05:58
2156
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
* Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience * Financing led by Frazier Life Sciences with significant participation from Jeito Capital alongside o...
2025-03-03 22:00
2756
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
* First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model * Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VA...
2025-03-03 21:00
1653
Sole Pharma - Launches in the Philippines to Meet Rising Demand for High-Quality Supplements
MANILA, Philippines, March 3, 2025 /PRNewswire/ -- In response to the growing demand for high-quality health supplements in the Philippines, Sole Pharma, as one of the leading Europeanpharmaceutical manufacturer, announces its expansion into the Southeast Asian market. Products are available onli...
2025-03-03 08:55
2244
Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2025-03-03 08:00
4340
Hospital Kuala Lumpur & Rare Disease Patient Organizations Nationwide Celebrate Rare Disease Day 2025
KUALA LUMPUR, Malaysia, March 1, 2025 /PRNewswire/ -- For the first time, Hospital Kuala Lumpur (HKL) is proudly hosting the annual Rare Disease Day 2025 celebration to raise awareness and advocate for individuals affected by rare diseases inMalaysia. This milestone event is organized by the Depa...
2025-03-01 22:30
4148
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
SHANGHAI, Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor...
2025-02-28 14:28
4301
Nezha Craze Sweeps the City Wai Yuen Tong Proudly Sponsors Broadcast of "Nezha: The Demon Child Comes into the World" on Jade Channel
HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Hong Kong's traditional Chinese medicine pioneer Wai Yuen Tong (0897.HK) announced its proud sponsorship of the TVB Jade Channel's broadcast of the film " Nezha: The Demon Child Comes into the World " (Nezha 1) onFebruary 28 at 8 PM. This film will provid...
2025-02-27 20:09
3123
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection byJapan's Pharmaceuticals and Medical Devices Agency (PMDA) for it...
2025-02-27 16:30
3407
Clarivate Report Explores Opportunities for Innovation and Market Expansion in Latin America
New insights from Clarivate examine strategic partnerships, API production, and innovation in the region LONDON, Feb. 27, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, has released a new white paper, How is Latin America Growing?, sheddi...
2025-02-27 16:00
1921
Alpro Foundation & Universiti Teknologi MARA: Addressing Malaysia's Pharmaceutical Waste
KUALA LUMPUR, Malaysia, Feb. 27, 2025 /PRNewswire/ -- Malaysia is facing a growing environmental and public health threat due to improper disposal of pharmaceutical waste. Research indicates that 67% of Malaysians discard expired medications incorrectly—either by flushing them down the toilet or ...
2025-02-27 15:19
2506
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer
SUZHOU, China, Feb. 27, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-301) of anti-HER2 bip...
2025-02-27 14:06
4108
Neopharma Technologies Announces Strategic Partnership with AusChain to Assist with the Scaling and Global Rollout of NEOVAULT®
PERTH, Australia, Feb. 27, 2025 /PRNewswire/ -- Neopharma Technologies Ltd (Neopharma) is pleased to announce a strategic partnership with AusChain Pty Ltd, a global leader in scalable blockchain solutions specializing in product traceability through QR codes. AusChain has successfully implemente...
2025-02-27 12:01
2550
AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials
Innovation and Global Expansion Attract Capital Reassessment AIM Vaccine Co., Ltd. (a joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 6660.HK) HONG KONG, Feb. 27, 2025 /PRNewswire/ -- The stocks in the Hong Kong pharmaceutical sector have ...
2025-02-27 08:00
4082
Shingles Awareness Week 2025: Shingles increases risk for heart attack and stroke; the disease also increases risk for hospitalisation more than thrice in people with diabetes
* People who have had shingles are at a 59% higher risk for heart attack and at a 35% higher risk for stroke compared to those who have not had shingles. * Adults aged 50 years or over are at high risk for shingles due to age-related decline in immunity and the risk further increases amongst t...
2025-02-26 14:45
2017
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025
* Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment * Etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal healing, endoscopic normalization, and histological remission * Safety profile remains c...
2025-02-26 07:45
2223
Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial res...
2025-02-25 18:28
2894
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.
Another Step Forward in Global Expansion HONG KONG, Feb. 25, 2025 /PRNewswire/ -- As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines inChina is in full swing. On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announce...
2025-02-25 08:00
2044
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 317 media titles]
2026-01-23 11:03
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 308 media titles]
2026-01-27 13:00
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 306 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 299 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
